Back to search results
NCT06679946

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Enrolling by Invitation
PHASE3Ages 18+InterventionalTreatment
Alnylam Pharmaceuticals
~700 participants
Updated 2026-02-20 on ClinicalTrials.gov
What's tested:Vutrisiran

At a glance

Recruiting sites
0 of 87 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Frequency of Adverse Events (AEs)
Measured over Up to 36 Months

Conditions

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Explore related trials

ATTR AmyloidosisTTR Gene

Where it's being run

87 sites across 34 states
Belgium8
Argentina7
United Kingdom7
Brazil5
France5
Spain5
Portugal4
California3

Study leadership

  • Medical Director · STUDY_DIRECTOR · Alnylam Pharmaceuticals

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients who are participating in the patisiran parent studies ALN-TTR02-011 or ALN-TTR02-014 or who have completed the 24-month OLE Period in the vutrisiran parent study ALN-TTRSC02-003

Exclusion

Has permanently discontinued study drug administration while participating in the parent studies, ALN-TTR02-011, ALN-TTR02-014, or ALN-TTRSC02-003
Future or current participation in another investigational device or drug study, scheduled to occur during this study
Has other medical conditions or comorbidities which, in the opinion of the Investigator, would interfere with study compliance or data interpretation

What this trial measures

  • Frequency of Adverse Events (AEs)Up to 36 Months

    An AE is any untoward medical occurrence in a patient or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.